Biosect,
What I do think is clear is that the company will hold up on issuing TLD until either Journal or presentation they're planning on is about to occur, likewise the update to clinical trials. I don't know how much time must be permitted for submission of a change to clinical trials, in that everything should reference the goals documented there, I would think that will be the first submission.
Others may believe we'll be going into next year with nothing resolved, I'm still of the belief that we'll have a Happy Holiday season, can't say it will be by Thanksgiving, but we still have well over a month to XMAS. I feel reasonably certain we'll have positive news on Sawston this year, but I'm expecting more than that.
Financially I believe that the company cannot indefinitely stay with the currently authorized shares. I believe some news will proceed them asking for a vote to authorize the additional shares, and frankly it ought to occur early next year or sooner. Of course LP can probably lend the company money herself, or has others she can go to with no share involvement, but I hope it doesn't come down to that. I would much rather see 10 to 100 million new shares sold, at $100 million to a billion in proceeds, i.e. $10 a share or more, than seeing a substantial loan at substantial interest rates. I would prefer to see no more warrants included with new stock offered for sale. Once we have TLD out I believe there will be no shortage of Institutions eager to take millions of shares at essentially market price if given the opportunity. I just want them to take the time needed to move the share price dramatically higher before doing anything like that.
Gary
News 
Market Data 
Discover 
AI
